



OLIGOMERIX, Inc.

Oligomerix, Inc. to Present Multiple Posters Highlighting its Tau-Focused Technology During the Annual Alzheimer's Association International Conference®

NEW YORK, NY, July 8, 2013: Oligomerix, Inc., a privately held biotechnology company pioneering the development of disease modifying therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, announced today the company will present three posters during the Alzheimer's Association International Conference® (AAIC) to be held July 13-18, 2013, in Bost, MA at the Boston Convention & Exhibition Center.

The posters will highlight Oligomerix's programs, which include the development of small molecules and antibodies aimed at reducing tau oligomer levels that are thought to be acutely toxic in diseases such as AD and other tauopathies.

Sunday, July 14, 2013:

Title: Detection of soluble oligomeric tau with morphology specific antibody fragments as a potential diagnostic for AD

Authors: Huilai Tian, Eliot Davidowitz, Ph.D., James Moe, Ph.D., Mike Sierks, Ph.D.

Poster: P1-212

Location: Exhibit Hall A (11:45 a.m. ET – 2:15 p.m. ET)

Title: Characterization of a novel monoclonal antibody specific for a tau autoproteolytic cut site that differentiates between AD and non-AD specimens

Authors: Eliot Davidowitz, Ph.D., Patricia Lopez, M.S., James Moe, Ph.D.

Poster: P1-411

Location: Exhibit Hall A (11:45 a.m. ET – 2:15 p.m. ET)

Wednesday, July 17, 2013:

Title: Small molecule lead identification for inhibition of tau

oligomer formation

Authors: James Moe, Ph.D., James Hendrix, Ph.D., Patricia Lopez,

M.S., Robert Kilkuskie, Ph.D., Steve Vroegop, M.S., Eliot

Davidowitz, Ph.D.

Poster: P4-423

Location: Exhibit Hall A (11:45 a.m. ET – 2:15 p.m. ET)

ABOUT OLIGOMERIX

Oligomerix, Inc. is focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The Company was founded in 2006 and is headquartered at Albert Einstein College of Medicine. The Company is seeking strategic partners to help accelerate these important programs. For more information, visit www.oligomerix.com.

DISCLAIMER

This program is supported by the National Institute on Aging of the National Institutes of Health under Award Number R43AG057325. The content is solely the responsibility of the Oligomerix and does not necessarily represent the official views of the National Institutes of Health.

Contacts:

Oligomerix, Inc.
James Moe, 646-373-6897
President & CEO
jmoe@oligomerix.com

Oligomerix, Inc.
Jack Pasini, 917-912-4088
Chief Commercial Officer
jpasini@oligomerix.com